Abstract
Although the discovery of effective anti-tuberculosis drugs has made uncomplicated spinal tuberculosis a medical disease, the advent of multi-drug-resistant Mycobacterium tuberculosis and the co-infection of HIV with tuberculosis have led to a resurgence of the disease recently. The principles of drug treatment of spinal tuberculosis are derived from our experience in treating pulmonary tuberculosis. Spinal tuberculosis is classified to be a severe form of extrapulmonary tuberculosis and hence is included in Category I of the WHO classification. The tuberculosis bacilli isolated from patients are of four different types with different growth kinetics and metabolic characteristics. Hence multiple drugs, which act on the different groups of the mycobacteria, are included in each anti-tuberculosis drug regimen. Prolonged and uninterrupted chemotherapy (which may be ‘short course’ and ‘intermittent’ but preferably ‘directly observed’) is effective in controlling the infection. Spinal Multi-drug-resistant TB and spinal TB in HIV-positive patients present unique problems in management and have much poorer prognosis. Failure of chemotherapy and emergence of drug resistance are frequent due to the failure of compliance hence all efforts must be made to improve patient compliance to the prescribed drug regimen.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Daniel TM (2006) The history of tuberculosis. Respir Med 100:1862–1870
Tuli SM (2010) Tuberculosis of the skeletal system, 4th edn. Jaypee Brothers Medical Publishers, New Delhi
Dye C, Watt CJ, Bleed DM et al (2005) Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 293:2767–2775
Bick KM (1976) Classics of orthopaedics. JB Lippincott Co., Philadelphia
Balasubramanian R, Rajeswari R, SanthaT (2004) How does management of extrapulmonary tuberculosis differ from that of pulmonary tuberculosis? In: Toman’s Tuberculosis case detection, monitoring, treatment, 2nd edn. WHO, Geneva
Raviglipone MC, O’Brien RJ (2008) Tuberculosis. In: Fauci AS, Braunwald E, Kasper DL et al (eds) Harrison’s principles of internal medicine. McGraw-Hill, New York, pp 1006–1020
Hong Kong Chest Service/British Medical Research Council (1987) Five-year follow-up of a controlled trial of five 6-month regimens of chemotherapy for pulmonary tuberculosis. Am Rev Respir Dis 136:339–342
Controlled trial of 2, 4, and 6 months of pyrazinamide in 6-month, three-times-weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin, and pyrazinamide (1991) Results at 30 months. Hong Kong Chest Service/British Medical Research Council. Am Rev Respir Dis 143:700–706
Toman K (2004) How many drug-resistant tubercle bacilli can be found in the sputum of patients who have never received treatment for tuberculosis? In: Toman’s tuberculosis case detection, monitoring, treatment, 2nd edn. WHO, Geneva
Grumbach F, Canetti G, Grosset J (1967) Late results of long-term intermittent chemotherapy of advanced, murine tuberculosis: limits of the murine model. Tubercle 48:11–26
Lotte A, Hatton F, Perdrizet S, Rouillon A (1964) A concurrent comparison of intermittent (twice-weekly) isoniazid plus streptomycin and daily isoniazid plus PAS in the domiciliary treatment of pulmonary tuberculosis. Bull World Health Organ 31:247–271
British Thoracic Association (1982) A controlled trial of six months chemotherapy in pulmonary tuberculosis. Second report: results during the 24 months after the end of chemotherapy. Am Rev Respir Dis 126:460–462
Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis (1978) First report. Am Rev Respir Dis 118:219–228
Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: the results up to 24 months (1979) Tubercle 60:201–210
Balasubramanian R (1991) Fully intermittent 6 months regimen for pulmonary tuberculosis in South India. Indian J Tuberc 38:51–53
Toman K (2004) Toman’s tuberculosis case detection, monitoring, treatment, 2nd edn. WHO, Geneva
Zhang Y, Wade MM, Scorpio A et al (2003) Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother 52:790–795
World Health Organization (2003) Treatment of Tuberculosis: guidelines for National Programmes. 3rd edn. WHO, Geneva, p 35
Toman K (2004) How does management of extrapulmonary tuberculosis differs from that of pulmonary tuberculosis? In: Toman’s tuberculosis case detection, monitoring, treatment, 2nd edn. WHO, Geneva
East African/British Medical Research Councils (1973) Controlled clinical trial of four short course (6-month) regimes of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1:1331–1339
Singapore Tuberculosis Service/British Medical Research Council (1981) Clinical trial of six-month and four-month regimes of chemotherapy in the treatment of pulmonary tuberculosis: the results up to 30 months. Tubercle 62:95–102
Tuberculosis Research Centre (2001) Low rate of emergence of drug resistance in sputum positive patients treated with short course chemotherapy. Int J Tuberc Lung Dis 5:40–45
Davidson BL (1998) A controlled comparison of directly observed therapy vs self-administered therapy for active tuberculosis in the urban United States. Chest 114:1239–1243
Weis SE, Slocum P, Blais F et al (1994) The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 330:1179–1184
Moore RD, Chaulk P, Griffiths R et al (1996) Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis. Am J Respir Crit Care Med 154:1013–1019
Prasad R (2007) Management of multi-drug resistant tuberculosis: practitioners view point. Indian J Tuberc 54:3–11
Almeida D, Mehta A, Rodriques C et al (2002) Comparison of drug resistance of tuberculosis from rural area Sakawar and urban tertiary care centre. In: Presented at 110th general meeting of ASM, Los Angeles, USA, Abstract U58
Mukherjee JS, Rich ML, Socci AR et al (2004) Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 363:474–481
WHO (2006) Guidelines for the programmatic management of drug resistant tuberculosis. WHO, Geneva
Lemaire R, Masson B (2000) Risk of transmission of blood-borne viral infection in orthopaedic and trauma surgery. J Bone Joint Surg Br 82:313–323
Raviglione MC, Harries AD, Msiska R et al (1997) Tuberculosis and HIV: current status in Africa. AIDS 11:S115–S123
Alwood K, Keruly J, Moore-Rice K et al (1994) Effectiveness of supervised, intermittent therapy for tuberculosis in HIV infected patients. AIDS 8:1103–1108
Okwera A, Whalen C, Byekwaso F et al (1994) Randomised trial of thiacetazone and rifampicin-containing regimens for pulmonary tuberculosis in HIV-infected Ugandans. Lancet 344:1323–1328
Burman WJ, Gallicano K, Peloquin C (1999) Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis. Clin Infect Dis 28:419–430
Burman WJ, Jones BE (2001) Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am J Respir Crit Care Med 164:7–12
Navas E, Martin-Davila P, Moreno L et al (2002) Paradoxical reactions of tuberculosis in patients with the acquired immunodeficiency syndrome who are treated with highly active antiretroviral therapy. Arch Intern Med 162:97–99
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rajasekaran, S., Khandelwal, G. Drug therapy in spinal tuberculosis. Eur Spine J 22 (Suppl 4), 587–593 (2013). https://doi.org/10.1007/s00586-012-2337-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00586-012-2337-5